India's Cohance Lifesciences climbs on second-half growth outlook despite Q1 loss
06/08/2026 06:20
BUZZ-India's Cohance Lifesciences climbs on second-half growth outlook despite Q1 loss ** Shares of Cohance Lifesciences COHA.NS rise 2.1% to 438.9 rupees
** Co expects improvement in Q2 and a return to year-on-year growth in H2, supported by secured orders and scheduled deliveries
** Drugmaker posts Q1 consolidated net loss of 241.2 million rupees ($2.54 million) versus 488.8 million rupees profit a year ago; revenue falls 23%
** Co says lower CDMO contribution, order phasing to H2 and negative operating leverage hurt earnings
** Over 3.4 mln shares traded, 5.1x the 30-day avg
** Stock rated "Hold" on avg; median PT 452.5 rupees - data compiled by LSEG
** Stock down 16.9% YTD
($1 = 95.1400 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
Recent news on Cohance Lifesciences
See all newsBrief: Cohance Lifesciences Names Abhimanyu Ojha As CFO
Brief: Cohance Lifesciences Says U.S. FDA Issues Form 483 With Five Observations For Jaggaiahpet Unit In Andhra Pradesh
India's Cohance Lifesciences falls after US FDA inspection at Telangana plant
Brief: Cohance Lifesciences Says Investment Of USD 18 Million In NJ Bio And Aruka Bio
India's Cohance Lifesciences climbs on second-half growth outlook despite Q1 loss